Peter Leedman is the Director of the Harry Perkins Institute of Medical Research (‘Perkins’), Head of the Perkins Laboratory for Cancer Medicine and Professor of Medicine (endocrinologist) at Royal Perth Hospital. He graduated in Medicine from The University of Western Australia, completed his PhD at the Walter and Eliza Hall Institute of Medical Research and undertook post-doctoral studies at Harvard Medical School. He is internationally recognised for his research on the molecular mechanisms of hormone action, especially in poor prognostic tumours, such as head, neck and liver cancer. He co-founded miReven, a spin out company established to commercialise a replacement therapy for cancer, and is driving this initiative towards an early phase clinical trial in patients with liver cancer. He is also Chairman of Linear Clinical Research Ltd, a world-class company specializing in early phase clinical trials, with a focus on cancer, which is a wholly owned subsidiary of the Harry Perkins Institute.